The content on this site is intended for healthcare professionals only
Dr Peter Voorhees speaks to ecancer about results from the phase 3 MonumenTAL 3 trial evaluating talquetamab, a GPRC5D targeting bispecific antibody, in combination with daratumumab with or without pomalidomide in patients with relapsed or refractory multiple myeloma after at least one prior line of therapy.
The study explores whether these novel combinations can improve outcomes compared with the standard daratumumab pomalidomide dexamethasone regimen.
At interim analysis, both talquetamab based regimens demonstrated a marked improvement in progression free survival, with sustained benefit across key patient subgroups.
Response rates were higher, with a substantial increase in deep responses including complete response and minimal residual disease negativity, highlighting the potency of these combinations in earlier relapse settings.
Dr Voorhees says that overall survival outcomes also favoured the talquetamab arms, reinforcing the clinical impact of these findings.
Read the related news story here.
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies
Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma
MS-553 shows promise in treating chronic lymphocytic leukaemia
